Terazosin

CHEMBL611 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

387.4 g/mol

LogP

1.4

Phase

4

This medication relaxes the muscles in blood vessel walls and the prostate, and is used to treat high blood pressure and the urinary symptoms of an enlarged prostate (BPH). It belongs to the alpha-blocker class and allows blood to flow more easily while also easing urination. A first-dose effect of dizziness or fainting can occur, so the initial dose is typically taken at bedtime.

분자량

387.4000 g/mol

LogP

1.40

TPSA

103.00 Å²

리핀스키 5의 법칙

통과

치료 영역

Benign Prostatic Hyperplasia Cardiovascular Disease Parkinson's Disease Stroke Type 2 Diabetes Hypertension Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC

InChI

InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)

Molecular Formula

C19H25N5O4

HBD / HBA

1 / 8

회전 가능 결합

4

무거운 원자

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This medication relaxes the muscles in blood vessel walls and the prostate, and is used to treat high blood pressure and the urinary symptoms of an enlarged prostate (BPH). It belongs to the alpha-blocker class and allows blood to flow more easily while also easing urination. A first-dose effect of dizziness or fainting can occur, so the initial dose is typically taken at bedtime.

Yes, Terazosin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL611. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5401. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Terazosin PillFYI에서

구조

핵심 데이터

분자식: C19H25N5O4
동의어: 2

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.